Bhatia Lab/ MIT / Oscar Requejo / iStock / Getty Images Plus

Ian Randall

By Ian Randall

Deputy Science Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


“Mini livers” that can be injected into the body to help take over the functions of a failing liver have been created by scientists from the Massachusetts Institute of Technology (MIT).

If realized clinically, the development could provide a lifeline for many of the more than 10,000 Americans with chronic liver disease currently waiting for a transplant—amid a present shortage of donor organs to match.

“We think of these as satellite livers,” explained paper author and biomedical engineer professor Sangeeta Bhatia in a statement.

Read More on Science

“If we could deliver these cells into the body while leaving the sick organ in place, that would provide booster function.”

In early studies in mice, the researchers have demonstrated that these engineered tissue grants successfully generate many of the enzymes and other proteins produced by real livers—and can remain viable in the body for at least two months.

The hydrogel microspheres (green), hepatocytes (magenta) and supporting fibroblasts (orange) are seen here immediately after injection (left) and 14 days later, having assembled into engineered tissue grafts (right)

...

Our largest solid internal organ, the liver, is responsible for a whopping 500 essential bodily functions relating to the regulation of chemicals in the blood—from the regulation of clotting to clearing out drugs and bacteria. Most of these functions are performed by special cells known as hepatocytes.

Over the last decade, Bhatia and her colleagues have been investigating ways that hepatocyte function might be restored without resorting to a surgical transplant.

One idea they explored involved embedding hepatocytes into a biologically compatible material like a hydrogel—a three-dimensional network of cross-linked polymers capable of absorbing relatively large volumes of water without dissolving.

The problem with this approach, however, is that the hydrogels themselves would also need to be surgically implanted. To get around this, the researchers looked for a means to inject hepatocytes into patients instead.

Their solution involved injecting not only the cells, but also microspheres of hydrogel that would help the hepatocytes both to stay together, but also to form connections with nearby blood vessels.

A remarkable property of hydrogel microspheres helps with this process—when closely packed together, the spheres behave like a liquid, allowing them to be injected via a syringe; yet once inside the body they are able to regain their solid structure.

Moreover, hydrogel microspheres have also shown promise in helping to heal wounds, as they help cells to migrate into the spaces between the spheres and build up new tissue. In this way, the MIT researchers were able to use the microspheres to help injected hepatocytes form a stable tissue graft.

By adding fibroblasts to the injected mixture—a type of supportive cell—the team were able to increase the hepatocyte’s odds of survival, and promote the growth of blood vessels into the graft.

“What we did is use this technology to create an engineered niche for cell transplantation,” explained paper author and biological engineer Vardhman Kumar in a statement.

“If the cells are injected in the absence of these spheres, they would not integrate efficiently with the host, but these microspheres provide the hepatocytes with a niche where they can stay localized and become connected to the host circulation much faster.”

An artist's digital cutaway of the human body, showing the liver in orange

...

Working with a specialist from the Koch Institute, the researchers developed a method to use ultrasound to both guide a syringe to the injection site—in the case of their experiments on mice, fat tissue in the belly—as well as monitor the ongoing stability of the implant.

“The new blood vessels formed right next to the hepatocytes, which is why they were able to survive,” Kumar said. “They were able to get the nutrients delivered right to them, they were able to function the way they're supposed to, and they produced the proteins that we expect them to.”

According to the researchers, the grafts could also be delivered to other sites in the body, including the spleen and in the vicinity of the kidneys.

“For a vast majority of liver disorders, the graft does not need to sit close to the liver,” Kumar noted. In fact, the injected cells are capable of functioning like their "native" counterparts just as long as they have enough space and access to the circulatory network.

The team reported that the injected hepatocyte cells remained operational for the full length of the study—eight weeks—suggesting that the therapy has potential as a long-term treatment for liver disease.

The hydrogel microspheres are fabricated using a microfluidic device, pictured

...

“The way we see this technology is it can provide an alternative to surgery, but it can also serve as a bridge to transplantation where these grafts can provide support until a donor organ becomes available,” explained Kumar.

He continued: “And if we think they might need another therapy or more grafts, the barriers to do that are much less with this injectable technology than undergoing another surgery.”

In addition, the team noted, the grafts could be used to help patients who are ineligible for transplant because doctors fear that they are not healthy enough to tolerate surgery.

With the concept as it currently stands, patients would need to take immunosuppressive drugs in order to use the mini livers. In the future, however, the team say it may be possible to develop versions with “stealthy” hepatocytes capable of evading immune rejection.

Alternatively, the hydrogel spheres could be adapted to deliver immunosuppressants locally to the injection site.

Do you have a tip on a health story that Newsweek should be covering? Do you have a question about chronic liver disease? Let us know via health@newsweek.com.

Reference

Kumar, V., Yun, J., Elledge, S. K., Henning, N., Grzelak, K. A., Westerfield, A. D., Stoddard, A., Oladimeji, F. A., Spanoudaki, V., Chakraborty, K., Patel, S. K., Fleming, H. E., Chen, C. S., & Bhatia, S. N. (2026). Image-guided injectable niche for hepatocyte transplantation. Cell Biomaterials. https://doi.org/10.1016/j.celbio.2026.100378

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines